menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Lilly Completes $3.2B Acquisition of Morphic

    CONTRACT PHARMA

    Lilly Completes Acquisition Of Morphic To Expand IBD Treatment Options

    PR NEWSWIRE

    Eli Lilly to acquire Morphic for $3.2 billion

    PRESS RELEASE

    Morphic to Participate in Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic Shows Real-Time Small Molecule Gut Cell Trafficking Inhibition

    GLOBENEWSWIRE

    Morphic to Participate in RBC Capital Markets Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic Announces Corporate Highlights And Financial Results For Q1 2024

    GLOBENEWSWIRE

    Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

    GLOBENEWSWIRE

    Morphic Therapeutic Taps Simon Cooper as Chief Medical Officer

    CONTRACT PHARMA

    Morphic to Participate in March Investor Conferences

    GLOBENEWSWIRE

    Morphic Announces Financial Results for the Full Year 2023

    GLOBENEWSWIRE

    Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Morphic to Present at November Investor Conferences

    GLOBENEWSWIRE

    Morphic Announces Financial Results for the Third Quarter 2023

    GLOBENEWSWIRE

    Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

    GLOBENEWSWIRE

    Morphic Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave

    GLOBENEWSWIRE

    Morphic`s stock sinks as data on oral Entyvio rival disappoint

    FIERCE BIOTECH

    Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057

    GLOBENEWSWIRE

    Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

    GLOBENEWSWIRE

    Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference

    GLOBENEWSWIRE

    Morphic Announces Financial Results for the Second Quarter 2023

    GLOBENEWSWIRE

    Morphic to Present at the Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic Presents Biomarker Data at DDW 2023 Supporting MORF-057 Program

    GLOBENEWSWIRE

    Morphic Therapeutic Announces Closing of Public Offering & Full Exercise

    GLOBENEWSWIRE

    Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering

    GLOBENEWSWIRE

    Morphic Therapeutic Announces Proposed Public Offering

    GLOBENEWSWIRE

    Morphic shares swing on study data for drug viewed as ‘oral Entyvio’

    BIOPHARMADIVE

    Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort

    GLOBENEWSWIRE

    Morphic Announces Corporate Highlights andFYR for the 1Q 2023

    GLOBENEWSWIRE

    Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023

    GLOBENEWSWIRE

    Morphic to Present at TD Cowen 43rd Annual Health Care Conference

    GLOBENEWSWIRE

    Morphic Announces Corporate Highlights and Financial Results for Full Year 2022

    GLOBENEWSWIRE

    Morphic to Present at SVB Leerink Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic loses second partner as J&J exits integrin alliance

    PHARMA PHORUM

    Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Morphic Therapeutic doses first subject in ulcerative colitis therapy trial

    CLINICALTRIALSARENA

    Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057

    GLOBENEWSWIRE

    Morphic Announces Financial Results for the Third Quarter 2022

    GLOBENEWSWIRE

    Morphic Presents New Positive MORF-057 Phase 1 Data

    GLOBENEWSWIRE

    Morphic Announces Complete Enrollment of EMERALD-1

    GLOBENEWSWIRE

    Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

    GLOBENEWSWIRE

    Morphic Celebrates Foundational Integrin Research Published in Cell

    GLOBENEWSWIRE

    Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference

    GLOBENEWSWIRE

    Morphic Announces Corporate Highlights and Financial Results for Q2 2022

    GLOBENEWSWIRE

    AbbVie walks away from Morphic deal due to safety signal in preclinical testing

    ENDPTS

    Morphic to Present at 2022 Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

    GLOBENEWSWIRE

    Morphic Names Bruce Rogers as President and Blaise Lippa as CSO

    GLOBENEWSWIRE

    Morphic Therapeutic Expands Leadership with Key Appointments

    GLOBENEWSWIRE

    Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

    GLOBENEWSWIRE

    Morphic Initiates EMERALD-1 Phase 2a Trial of MORF-057 in Ulcerative Colitis

    GLOBENEWSWIRE

    Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference

    GLOBENEWSWIRE

    AbbVie ditches Morphic`s fibrosis program after `safety signal`

    FIERCEBIOTECH

    Morphic Announces Corporate Highlights and Financial Results for Full Year 2021

    GLOBENEWSWIRE

    Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022

    GLOBENEWSWIRE

    Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results

    GLOBENEWSWIRE

    Morphic announces positive results from phase 1 trial of MORF-057

    PHARMABIZ

    Morphic announces positive results from phase 1 trial of MORF-057

    PHARMABIZ

    Morphic announces positive results from phase 1 trial of MORF-057

    PHARMABIZ

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.